Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Platinum-based chemotherapy doesn't just fight cancer — it quietly ages children's healthy cells. Two landmark studies reveal that chemo leaves distinct DNA "fingerprints" across tissues, including a previously unknown damage pattern in the liver, helping explain why childhood cancer survivors often face secondary cancers and other health problems decades later.
Two major studies are reshaping our understanding of what childhood chemotherapy does to the body long after treatment ends. Research published in Science by teams at the Wellcome Sanger Institute, University of Cambridge, Francis Crick Institute, and King's College London found that platinum-based chemotherapy causes extensive DNA damage in healthy tissues — so much so that a child's cells can end up carrying the same number of mutations typically seen in middle-aged adults. The study also uncovered a previously unknown pattern of DNA damage specific to the liver, likely caused by how the drug is metabolized in that organ.
A complementary study published in Nature and led by SickKids found that nearly half of childhood tumors treated with platinum-based chemo showed detectable genomic "fingerprints" within just 18 months of treatment — some as early as 91 days in. Researchers say these signatures could one day serve as an early warning system, helping clinicians spot treatment resistance before cancer returns.
By the Numbers:
Why it matters: These findings offer a plausible biological explanation for the "premature aging" health issues — secondary cancers, liver disease, cardiac problems — that childhood cancer survivors often face. The goal isn't to abandon chemotherapy, which remains essential, but to use these insights to develop protective strategies and more precisely tailored treatment plans.
